# Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

> **NCT06802848** · — · NOT_YET_RECRUITING · sponsor: **Chongqing Genrix Biopharmaceutical Co., Ltd** · enrollment: 1000 (estimated)

## Conditions studied

- Plaque Psoriasis
- Psoriatic Arthritis
- Scalp Psoriasis
- Nail Psoriasis
- Palmoplantar Psoriasis
- Genital Psoriasis

## Interventions

- **DRUG:** Xeligekimab injection

## Key facts

- **NCT ID:** NCT06802848
- **Lead sponsor:** Chongqing Genrix Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802848, "Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06802848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*